MedTrace Logo

Iron Supplementation in Upper Non-variceal Gastrointestinal Bleeding

NCT05060731 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 570

Last updated 2025-03-30

No results posted yet for this study

Summary

Anemia is a frequent complication of gastrointestinal bleeding, affecting 61% of the patients. Currently, anemia caused by gastrointestinal bleeding can be treated with iron supplementation. However, the dose and route of the administration are still a question. The FIERCE clinical trial aims to compare the effect of intravenous iron supplementation and oral iron replacement on mortality, unplanned emergency visits, and hospital readmissions in multimorbid patients with acute nonvariceal gastrointestinal bleeding.

Conditions

  • GastroIntestinal Bleeding
  • Anemia

Interventions

DRUG

Oral iron supplementation

Ca. 200-300 mg of ferrous sulfate will be administered orally every day for 3 months.

DRUG

Intravenous iron supplementation

One dose of intravenous 1000 mg ferric carboxymaltose will be administered on the day of randomization.

Sponsors & Collaborators

  • University of Pecs

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-01
Primary Completion
2027-12-31
Completion
2028-02-01

Countries

  • Hungary

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05060731 on ClinicalTrials.gov